Hyperion Defi, Inc. HYPD
Biotechnology: Pharmaceutical Preparations · IPO 2018 · data as of November 13, 2026
Hyperion Defi, Inc. (HYPD) is a healthcare company listed in the US with a market value of about $40M. In the twelve months to September 30, 2026 it had revenue of $2M and net income of $40M, a net margin of 2075.4%.
Its overall Stock Analiz score is 1.6 out of 5 (weak). The strongest part is value (3/5); the weakest is track record (0/5).
Key numbers: a P/E of 1.0, 5-year revenue growth of -16% a year, a 5-year average ROIC of -65%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 30% above the current price.
About Hyperion Defi
Hyperion Defi is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2018. Revenue went from $2M in 2020 to $813455 in 2025, a decline of about 16.5% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 1089% over three years (dilution for shareholders). It spends 235% of revenue on research and development.
Score: 1.6 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/FCF below 20
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2M | $813455 | $57336 | $3787 | — | $14M | $2M | — | — | — | — |
| Net income | $40M | -$45M | -$50M | -$27M | -$28M | -$13M | -$20M | -$21M | -$17M | -$5M | -$4M |
| Free cash flow | — | — | -$30M | -$27M | -$26M | -$22M | -$7M | -$19M | -$13M | -$5M | -$3M |
| EPS (diluted) | $2.64 | $-3.13 | $-19.94 | $-17.72 | $-22.13 | $-13.07 | $-25.07 | $-39.20 | $-48.53 | $-58.40 | $-41.60 |
| Net margin | 2075.4% | -5570.6% | -86888.6% | -719900.0% | — | -91.3% | -988.5% | — | — | — | — |
| ROIC | — | -73.6% | — | -75.9% | -73.2% | -36.8% | -99.2% | -143.4% | -80.8% | -79.7% | -92.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 2 analysts is $9.82, 281% above the current price; targets range from $8.45 to $11.20; the consensus rating is “Strong buy”; expected EPS is $5.78 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Hyperion Defi’s P/E ratio?
About 1.0, based on the last twelve months of diluted earnings per share (forward P/E about 1.5).
Is Hyperion Defi stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 30% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Hyperion Defi pay a dividend?
Not currently.
Is Hyperion Defi a good stock to buy?
We do not give buy or sell advice. Hyperion Defi scores 1.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.